AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BerGenBio

Share Issue/Capital Change Oct 4, 2021

3555_rns_2021-10-04_c5c1f800-59c7-4363-8830-15bcf8addc08.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

BerGenBio ASA: Share capital increase

BerGenBio ASA: Share capital increase

Bergen, Norway, 4 October 2021 - Reference is made to the stock exchange notice

published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 30 September 2021

where the Company announced that the board of directors of the Company had

resolved to increase the Company's share capital in connection with the exercise

of options pursuant to the Company's share option program. A total of 137,500

options were exercised and 137,500 new shares were issued at an average

subscription price of NOK 16.01 per share.

The share capital increase has been duly registered in the Norwegian Register of

Business Enterprises. Following such registration, the Company's share capital

is NOK 8,838,525.50 divided into 88,385,255 shares, each with a nominal value of

NOK 0.10.

-End-

Contacts

Rune Skeie

CFO, BerGenBio ASA

[email protected]

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.